For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
GPs expecting specialist rights for ‘2 per cent-plus' cannabis products
+News
In print
Summer Hiatus
GPs expecting specialist rights for ‘2 per cent-plus' cannabis products
Monday 6 January 2020, 09:00 AM

We are on our summer break and the editorial office is closed until 13 January. We hope you enjoy this article which is part of Summer Hiatus, an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading
Kiwi medicinal cannabis companies got fired up this year, and GPs will soon find it easy to prescribe the products. Simon Maude reports on the emergin, Graham Gulbransen 2017, Auckland GP Graham Gulbransen, who specialises in addiction, says he is comfortable with changes to medicinal cannabis regulations
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.